News & Updates
Filter by Specialty:
Toripalimab plus bevacizumab, SoC demonstrates promising efficacy for cervical cancer
Preliminary results of a single-arm, open-label, phase II trial demonstrated the efficacy of a combination regimen comprising toripalimab, bevacizumab, and platinum-based chemotherapy for women with refractory, recurrent, or metastatic cervical cancer.
Toripalimab plus bevacizumab, SoC demonstrates promising efficacy for cervical cancer
15 May 2023
Temporary ET break for pregnancy safe in the short term for breast cancer survivors
Temporary interruption of adjuvant endocrine therapy (ET) to allow for pregnancy has demonstrated short-term safety, with no increase in risk of breast cancer events, including distant recurrence, in hormone receptor–positive breast cancer survivors who have completed 18–30 months of adjuvant ET.
Temporary ET break for pregnancy safe in the short term for breast cancer survivors
09 May 2023
Hysteroscopic resection outdoes ultrasound-guided D&E for caesarean scar ectopic pregnancy
Treatment success of caesarean scar ectopic pregnancy appears to be higher with hysteroscopic resection than with ultrasound-guided dilation and evacuation (D&E), according to a study.
Hysteroscopic resection outdoes ultrasound-guided D&E for caesarean scar ectopic pregnancy
06 May 2023
Surgery, but not chemo, may benefit patients with rare ovarian neoplasms
Good quality surgery conferred a progression-free survival (PFS) benefit for women with ovarian sex cord stromal tumours (SCST) in the first-line setting and on first and second relapse. Chemotherapy, on the other hand, had no impact on survival in the first-line or relapse setting.
